From: maha on
About two years ago, I wandered in here and lurked for awhile as I was
starting treatment for my Hep C. Never participated much, but I did
like reading posts from people who were going through the same thing I
was. I failed to get an SVR. In fact, the virus had returned in week
24 but due to problems with the lab, I didin't even find out until a
year after my treatment had ended. As you can understand, I was
crestfallen and a bit angry that I had been subjected to an additional
5 months of unnecessary side effects.

There is a new study that is specifically for Genotype 1 patients that
did not respond to the conventional therpay. It's the same drill with
the peg-intron and ribavirin, excepth they have added an experimental
drug called boceprevir (a protease inhibitor) which has it's own set
of delightful side effects.. From what I understand, the initial
results have been very promising.

I start again Friday. I have this unreal since of dread about the 48
weeks of feeling ill, but I still think it's the right thing to do.

Graham
From: greyhackles on
On Wed, 22 Oct 2008 18:55:43 -0500, maha <rgf3(a)RemovEbellsouth.net> wrote:

>About two years ago, I wandered in here and lurked for awhile as I was
>starting treatment for my Hep C. Never participated much, but I did
>like reading posts from people who were going through the same thing I
>was. I failed to get an SVR. In fact, the virus had returned in week
>24 but due to problems with the lab, I didin't even find out until a
>year after my treatment had ended. As you can understand, I was
>crestfallen and a bit angry that I had been subjected to an additional
>5 months of unnecessary side effects.
>
>There is a new study that is specifically for Genotype 1 patients that
>did not respond to the conventional therpay. It's the same drill with
>the peg-intron and ribavirin, excepth they have added an experimental
>drug called boceprevir (a protease inhibitor) which has it's own set
>of delightful side effects.. From what I understand, the initial
>results have been very promising.
>
>I start again Friday. I have this unreal since of dread about the 48
>weeks of feeling ill, but I still think it's the right thing to do.
>
>Graham

Yup, Boceprevir is Schering-Plough's candidate alternative to Vertex's
Telaprevir. Both are protease inhibitors, and both are showing solid
enhancement of SVR rates when combined with the conventional therapy drugs.
Telaprevir has been in Phase 3 studies, while Boceprevir is in Stage 2, but
coming on strong from all the reports.

Cheers - and here's hoping you are in the study arm that gets the Boceprevir!

/greyhackles
From: Paul on
On Wed, 22 Oct 2008 18:55:43 -0500, maha <rgf3(a)RemovEbellsouth.net>,
in message ID <h9fvf4dmugu3m9h6nge957oc1dmk06gg4n(a)4ax.com>, in the
newsgroup alt.support.hepatitis-c wrote:

>About two years ago, I wandered in here and lurked for awhile as I was
>starting treatment for my Hep C. Never participated much, but I did
>like reading posts from people who were going through the same thing I
>was. I failed to get an SVR. In fact, the virus had returned in week
>24 but due to problems with the lab, I didin't even find out until a
>year after my treatment had ended. As you can understand, I was
>crestfallen and a bit angry that I had been subjected to an additional
>5 months of unnecessary side effects.
>
>There is a new study that is specifically for Genotype 1 patients that
>did not respond to the conventional therpay. It's the same drill with
>the peg-intron and ribavirin, excepth they have added an experimental
>drug called boceprevir (a protease inhibitor) which has it's own set
>of delightful side effects.. From what I understand, the initial
>results have been very promising.
>
>I start again Friday. I have this unreal since of dread about the 48
>weeks of feeling ill, but I still think it's the right thing to do.

Welcome back. I'm glad I only needed one stab at tx and I feel for
you. I'm disgusted that you were subjected to so much unnecessary tx
as well. Not the worst horror story I've heard but certainly a
candidate for the top 20%.
Best of luck with it this time around.